These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 29412698)

  • 1. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A role for tubular Na
    Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1.
    Novikov A; Fu Y; Huang W; Freeman B; Patel R; van Ginkel C; Koepsell H; Busslinger M; Onishi A; Nespoux J; Vallon V
    Am J Physiol Renal Physiol; 2019 Jan; 316(1):F173-F185. PubMed ID: 30427222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
    Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
    PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A role for the organic anion transporter OAT3 in renal creatinine secretion in mice.
    Vallon V; Eraly SA; Rao SR; Gerasimova M; Rose M; Nagle M; Anzai N; Smith T; Sharma K; Nigam SK; Rieg T
    Am J Physiol Renal Physiol; 2012 May; 302(10):F1293-9. PubMed ID: 22338083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
    Rieg T; Masuda T; Gerasimova M; Mayoux E; Platt K; Powell DR; Thomson SC; Koepsell H; Vallon V
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F188-93. PubMed ID: 24226519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
    Panchapakesan U; Pegg K; Gross S; Komala MG; Mudaliar H; Forbes J; Pollock C; Mather A
    PLoS One; 2013; 8(2):e54442. PubMed ID: 23390498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
    Reyes-Pardo H; Bautista R; Vargas-Robles H; Rios A; Sánchez D; Escalante B
    BMC Nephrol; 2019 Aug; 20(1):292. PubMed ID: 31375080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
    PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
    Dailey GE
    Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats.
    Gal A; Burton SE; Weidgraaf K; Singh P; Lopez-Villalobos N; Jacob A; Malabu U; Burchell R
    Domest Anim Endocrinol; 2020 Jan; 70():106376. PubMed ID: 31585313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake.
    Albalawy WN; Youm EB; Shipman KE; Trull KJ; Baty CJ; Long KR; Rbaibi Y; Wang XP; Fagunloye OG; White KA; Jurczak MJ; Kashlan OB; Weisz OA
    Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1041-F1053. PubMed ID: 38660713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules.
    Li J; Liu H; Takagi S; Nitta K; Kitada M; Srivastava SP; Takagaki Y; Kanasaki K; Koya D
    JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32134397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro.
    Baer PC; Koch B; Freitag J; Schubert R; Geiger H
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.
    Ghezzi C; Yu AS; Hirayama BA; Kepe V; Liu J; Scafoglio C; Powell DR; Huang SC; Satyamurthy N; Barrio JR; Wright EM
    J Am Soc Nephrol; 2017 Mar; 28(3):802-810. PubMed ID: 27620988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 mediates glucose reabsorption in the early proximal tubule.
    Vallon V; Platt KA; Cunard R; Schroth J; Whaley J; Thomson SC; Koepsell H; Rieg T
    J Am Soc Nephrol; 2011 Jan; 22(1):104-12. PubMed ID: 20616166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.
    Sarashina A; Koiwai K; Seman LJ; Yamamura N; Taniguchi A; Negishi T; Sesoko S; Woerle HJ; Dugi KA
    Drug Metab Pharmacokinet; 2013; 28(3):213-9. PubMed ID: 23149871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.